Search
Search Results
-
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy
On August 30, 2023, experts from Germany and abroad met to discuss the successes and challenges of cytokine-induced killer cell (CIK) therapy, that...
-
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Adoptive immunotherapy in the T cell landscape exhibits efficacy in cancer treatment. Over the past few decades, genetically modified T cells,...
-
Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma
IntroductionNatural killer cells can attack cancer cells without prior sensitization, but their clinical benefit is limited owing to their poor...
-
Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia
Allogeneic natural killer (NK) cell-based immunotherapy is a promising, well-tolerated adjuvant therapeutic approach for acute myeloid leukemia...
-
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), such as anti-programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) therapy, has...
-
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial
Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer...
-
HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia
Allogeneic hematopoietic stem cell transplantation (HSCT) is still needed for many children with very high-risk acute leukemia. An HLA-haploidentical...
-
Enhanced cellular therapy: revolutionizing adoptive cellular therapy
Enhanced cellular therapy has emerged as a novel concept following the basis of cellular therapy. This treatment modality applied drugs or...
-
Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence
Using the particular nature of melanoma mutanomes to develop medicines that activate the immune system against specific mutations is a game changer...
-
Challenges and new technologies in adoptive cell therapy
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to the subsequent specific...
-
The past, present, and future of immunotherapy for colorectal cancer
Colorectal cancer is prevalent worldwide, with various factors influencing the survival rate of late-stage metastatic cases. Current standard...
-
Immunotherapy in HPV-Related Oropharyngeal Cancers
Human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma (OPSCC) incidence has been increasing in recent decades. Treatment of the...
-
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy
Clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) is essentially an adaptive immunity weapon in...
-
Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials
BackgroundThyroid cancer is a leading endocrine malignancy, with anaplastic and medullary subtypes posing treatment challenges. Existing therapies...
-
The past, present, and future of immunotherapy for endometrial adenocarcinoma
Incidences of endometrial adenocarcinoma are increasing in the USA with poor prognosis for patients with advanced disease. The current treatment...
-
Immunotherapy in Head and Neck Cancer: Where Do We Stand?
Purposeof ReviewHead and neck cancer (HNC) comprises a group of malignancies, amongst which squamous cell carcinoma accounts for more than 90% of the...
-
Breast cancer immunotherapy: a comprehensive review
Cancer remains a major health problem despite numerous new medical interventions that have been introduced in recent years. One of the major choices...
-
A phase I/II study of adoptive immunotherapy using donor liver graft-derived natural killer cells to prevent bloodstream infection after liver transplantation: a study protocol
BackgroundBloodstream infections (BSIs) are among the most lethal complications of liver transplantation (LT). Natural killer (NK) cells are an...
-
Current approaches in glioblastoma multiforme immunotherapy
Glioblastoma multiform (GBM) is the most prevalent CNS (central nervous system) tumor in adults, with an average survival length shorter than 2 years...
-
Intratumoral adoptive transfer of inflammatory macrophages engineered by co-activating TLR and STING signaling pathways exhibits robust antitumor activity
Despite the success of chimeric antigen receptor (CAR) T cells in hematologic malignancies, adoptive cell therapy (ACT) has not been effective in...
